PegBio Co Ltd

PegBio's capital structure is characterized by a debt-to-equity ratio of 0.21, indicating a relatively low level of leverage. The company's liquidity position is assessed as medium, with a current ratio of 3.94, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's operating cash flow is negative at -151.9 million CNY, and its free cash flow is also negative at -208.5 million CNY, indicating ongoing cash outflows from operations. In terms of profitability, PegBio reported a net loss of 208.4 million CNY and an operating loss of 205.8 million CNY, resulting in a return on equity of -46.46% and a return on assets of -34.77%. These figures are significantly below the industry norms for profitability and returns, as outlined in the industry_config preferred metrics. The company's revenue is not disclosed in the latest financial data, making it difficult to assess its geographic and segment exposure. However, the lack of revenue data suggests a potential concentration risk, as the company's financial performance is not diversified across multiple segments or regions. PegBio's growth trajectory is uncertain, as the company is currently reporting losses and negative cash flows. The absence of revenue data and the lack of analyst price targets beyond a mean of 12.00 CNY suggest limited visibility into the company's future performance. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity challenges. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. Recent events and filings do not provide specific details on the company's operations or strategic initiatives. The lack of detailed information in the latest financial data and the absence of revenue figures suggest that the company may be in an early stage of development or facing operational challenges.